DBD vs VYX: stock comparison and AI forecast
Diebold Nixdorf, Inc (DBD) and Ncr Voyix Corp (VYX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DBD Diebold Nixdorf, Inc
- Market Cap
- $1.96B
- P/E Ratio
- 36.0x
- Size
- small-cap
- AI Forecast
VYX Ncr Voyix Corp
- Price
- $9.86 +21.9% · 6M
- Market Cap
- $1.36B
- P/E Ratio
- 16.2x
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- DBD is 1.4 times larger than VYX by market capitalization ($1.96B against $1.36B).
- VYX trades at 16.2 times trailing earnings, DBD at 36.0 times.
- VYX turns 5.0% of its revenue into net income, against 2.0% for DBD.
- DBD carries 2.90 times debt per unit of equity, against 2.75 times for VYX.
- Both companies share the SEC industry classification Calculating & Accounting Machines (No Electronic Computers).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DBD | VYX |
|---|---|---|
| Market Cap | $1.96B | $1.36B |
| P/E Ratio | 36.00x | 16.16x |
| P/B Ratio | 2.09x | 1.43x |
| EPS | $1.62 | $0.61 |
| Book Value/Share | $27.87 | $6.90 |
| Revenue/Share | $116.75 | $17.30 |
| FCF/Share | – | $-0.90 |
Profitability & Margins
| Metric | DBD | VYX |
|---|---|---|
| ROE | 8.2% | 12.5% |
| ROA | 2.1% | 3.1% |
| ROIC | 8.9% | 1.9% |
| Gross Margin | 25.0% | – |
| Operating Margin | 5.4% | 2.3% |
| Net Margin | 2.0% | 5.0% |
| EBT Margin | 3.1% | 0.0% |
| Tax Rate | 34.8% | – |
Financial Health
| Metric | DBD | VYX |
|---|---|---|
| Current Ratio | 1.27x | 1.11x |
| Quick Ratio | 0.84x | 0.98x |
| D/E Ratio | 2.90x | 2.75x |
| Financial Leverage | 3.91x | 3.96x |
| Interest Coverage | 0.5x | 2.6x |
| Working Capital | $352M | $104M |
Cash Flow
| Metric | DBD | VYX |
|---|---|---|
| Operating Cash Flow | $188M | $136M |
| Free Cash Flow | – | -$124M |
| Capital Spending | – | -$260M |
| OCF Growth YoY | -32.6% | – |
| FCF/Sales | – | -5.2% |
| CapEx/Sales | – | 10.9% |
Operational Efficiency
| Metric | DBD | VYX |
|---|---|---|
| Asset Turnover | 1.07x | 0.63x |
| Receivables Turnover | 6.8x | 5.8x |
| Inventory Turnover | 5.2x | – |
| Fixed Assets Turnover | 27.9x | 14.7x |
| Days Sales Outstanding | 54 days | 63 days |
| Days Inventory | 70 days | – |
| Payables Period | 61 days | – |
| Cash Conversion Cycle | 62 days | – |
Income Statement
| Metric | DBD | VYX |
|---|---|---|
| Total Revenue | $3.92B | $2.39B |
| Operating Income | $211M | $54M |
| Net Income | $77M | $119M |
| R&D Expense | $84M | $143M |
| SG&A Expense | $667M | $446M |
| Cost of Goods Sold | $2.94B | – |
Dividend & Shareholder Information
| Metric | DBD | VYX |
|---|---|---|
| Shares Outstanding | 34M | 138M |
| Net Income Growth | 50.7% | – |
| EPS Growth | 27.6% | – |
DBD vs VYX: stock comparison and AI forecast
Which is bigger, DBD or VYX?
DBD is 1.4 times larger than VYX by market capitalization ($1.96B against $1.36B).
Which is cheaper on earnings, DBD or VYX?
VYX trades at 16.2 times trailing earnings, DBD at 36.0 times.
Which one does Intratio's AI model rank higher, DBD or VYX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.